Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,434.15 25.61 0.16%
S&P 500 1,869.27 4.42 0.24%
NASDAQ 4,108.08 12.56 0.31%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

Keryx Biopharmaceuticals, Inc. To Host Conference Call on Fourth Quarter and Year-End 2012 Financial Results



 Keryx Biopharmaceuticals, Inc. To Host Conference Call on Fourth Quarter and
                       Year-End 2012 Financial Results

Investor Conference Call to be held Tomorrow, Tuesday, March 12, 2013 at
8:30am EDT

PR Newswire

NEW YORK, March 11, 2013

NEW YORK, March 11, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc.
(NASDAQ: KERX), a biopharmaceutical company focused on the acquisition,
development and commercialization of medically important pharmaceutical
products for the treatment of renal disease, today announced that a conference
call will be held tomorrow, Tuesday, March 12, 2013 at 8:30 a.m. EDT to
discuss the Company's fourth quarter and year-end 2012 financial results and
provide a business outlook for 2013.  Ron Bentsur, Chief Executive Officer of
Keryx, will host the call.

In order to participate in the conference call, please call 1-877-869-3847
(U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio
recording of the conference call will be available for replay at
http://www.keryx.com, for a period of 15 days after the call.

Keryx will announce its financial results for this period in a press release
to be issued prior to the call.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an
oral, ferric iron-based compound that has the capacity to bind to phosphate
and form non-absorbable complexes. Keryx has completed a U.S.-based Phase 3
clinical program for Zerenex for the treatment of hyperphosphatemia (elevated
phosphate levels) in patients with end-stage renal disease, conducted pursuant
to a Special Protocol Assessment (SPA) agreement with the FDA, and Keryx
expects to submit a New Drug Application (NDA) with the FDA in the second
quarter of 2013 and a Marketing Authorization Application (MAA) with the EMA
in mid-2013.  Zerenex is also in Phase 2 development in the U.S. for the
management of phosphorus and iron deficiency in anemic patients with Stages 3
to 5 non-dialysis dependent chronic kidney disease.  In addition, Keryx's
Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has
filed its New Drug Application for marketing approval of ferric citrate in
Japan for the treatment of hyperphosphatemia in patients with chronic kidney
disease.  Keryx is headquartered in New York City.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

SOURCE Keryx Biopharmaceuticals, Inc.

Website: http://www.keryx.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement